JP2015529655A - アテローム性硬化症の処置方法 - Google Patents

アテローム性硬化症の処置方法 Download PDF

Info

Publication number
JP2015529655A
JP2015529655A JP2015525554A JP2015525554A JP2015529655A JP 2015529655 A JP2015529655 A JP 2015529655A JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015525554 A JP2015525554 A JP 2015525554A JP 2015529655 A JP2015529655 A JP 2015529655A
Authority
JP
Japan
Prior art keywords
registered trademark
simvastatin
peptide
lovastatin
release agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015525554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529655A5 (cg-RX-API-DMAC7.html
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
マーク バンバーガー
マーク バンバーガー
ブライアン ブレイキー
ブライアン ブレイキー
Original Assignee
ステルス ペプチドズ インターナショナル インコーポレイテッド
ステルス ペプチドズ インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス ペプチドズ インターナショナル インコーポレイテッド, ステルス ペプチドズ インターナショナル インコーポレイテッド filed Critical ステルス ペプチドズ インターナショナル インコーポレイテッド
Publication of JP2015529655A publication Critical patent/JP2015529655A/ja
Publication of JP2015529655A5 publication Critical patent/JP2015529655A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015525554A 2012-08-02 2013-07-31 アテローム性硬化症の処置方法 Pending JP2015529655A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695850P 2012-08-31 2012-08-31
US201261695807P 2012-08-31 2012-08-31
US61/695,850 2012-08-31
US61/695,807 2012-08-31
PCT/US2013/053007 WO2014022551A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017195835A Division JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法

Publications (2)

Publication Number Publication Date
JP2015529655A true JP2015529655A (ja) 2015-10-08
JP2015529655A5 JP2015529655A5 (cg-RX-API-DMAC7.html) 2016-09-15

Family

ID=50028503

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015525554A Pending JP2015529655A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015525555A Pending JP2015524439A (ja) 2012-08-02 2013-07-31 アテローム性硬化症の処置方法
JP2017194137A Pending JP2018016637A (ja) 2012-08-02 2017-10-04 アテローム性硬化症の処置方法
JP2017195835A Pending JP2018012726A (ja) 2012-08-02 2017-10-06 アテローム性硬化症の処置方法
JP2019042213A Pending JP2019108389A (ja) 2012-08-02 2019-03-08 アテローム性硬化症の処置方法

Country Status (8)

Country Link
US (5) US10188693B2 (cg-RX-API-DMAC7.html)
EP (6) EP3662921A1 (cg-RX-API-DMAC7.html)
JP (5) JP2015529655A (cg-RX-API-DMAC7.html)
CN (3) CN110090304A (cg-RX-API-DMAC7.html)
AU (4) AU2013296494B2 (cg-RX-API-DMAC7.html)
CA (2) CA2880643A1 (cg-RX-API-DMAC7.html)
HK (2) HK1210962A1 (cg-RX-API-DMAC7.html)
WO (2) WO2014022551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107312066A (zh) * 2011-12-09 2017-11-03 康德生物医疗技术公司 芳香族阳离子肽及其用途
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
CN110193077A (zh) * 2012-10-22 2019-09-03 康德生物医疗技术公司 降低与心脏衰竭相关的风险和与其相关的因素的方法
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
ES2871783T3 (es) * 2016-09-20 2021-11-02 Univ Aarhus Compuestos para el tratamiento de trastornos del metabolismo de las lipoproteínas
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
IL322723A (en) 2017-04-05 2025-10-01 Stealth Biotherapeutics Inc Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
CA2455336A1 (en) 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
PT1599216E (pt) * 2003-02-04 2013-12-17 Cornell Res Foundation Inc Métodos de prevenção da transição de permeabilidade mitocondrial
DK2604285T3 (en) * 2003-05-01 2014-12-01 Cornell Res Foundation Inc Method and carrier complex for delivering molecules to cells
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP2009525281A (ja) * 2006-01-30 2009-07-09 イスラエル ベン デビッド ブライソン、 心臓血管系疾患、脳血管系疾患および他の血管系疾患の患者を治療するための組成物ならびに方法
JP4881385B2 (ja) 2006-08-30 2012-02-22 国立大学法人九州大学 スタチン封入ナノ粒子含有医薬組成物
WO2009092071A2 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof
DK2252312T3 (da) * 2008-02-07 2014-06-16 Univ Cornell Fremgangsmåder til forebyggelse eller behandling af insulinresistens
EP3338788A1 (en) * 2009-08-24 2018-06-27 Stealth Peptides International, Inc. Methods and copositions for preventing or treating opthalmic conditions
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3040080A1 (en) * 2010-03-15 2016-07-06 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039766A1 (en) * 2009-08-12 2011-02-17 Szeto Hazel H Methods for preventing or treating metabolic syndrome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
下山立志 外1名: ""配合剤を構成する医薬品のプロフィル−4 スタチン系薬剤"", 薬局, vol. 61, no. 12, JPN6017012242, November 2010 (2010-11-01), JP, pages 3481 - 3485, ISSN: 0003534338 *
吉田茂: ""クレストール錠の安全性とＬＤＬ-Ｃ／ＨＤＬ-Ｃ比への作用の検討 −クレストール錠使用成績調査からの考察", 医学と薬学, vol. 59, no. 3, JPN6017012244, March 2008 (2008-03-01), JP, pages 357 - 380, ISSN: 0003534339 *
多田紀夫: ""特集 スタチン系薬物の有用性と実際の応用 −特に新しいピタバスタチンをめぐって− 4. スタチン系薬物の", PROG. MED., vol. 24, no. 1, JPN6017012240, January 2004 (2004-01-01), JP, pages 27 - 33, ISSN: 0003534337 *
大関健志 外1名: ""<研究報告> 薬物動態からみたスタチン系薬剤の有効性・安全性"", 日本医事新報, JPN6017012238, 20 May 2006 (2006-05-20), JP, pages 65 - 69, ISSN: 0003534336 *

Also Published As

Publication number Publication date
US10188693B2 (en) 2019-01-29
AU2013296494A1 (en) 2015-02-26
EP2879688A4 (en) 2015-12-16
EP2879689A1 (en) 2015-06-10
US20180344797A1 (en) 2018-12-06
JP2015524439A (ja) 2015-08-24
HK1210962A1 (en) 2016-05-13
AU2013296494B2 (en) 2018-04-26
US20180339012A1 (en) 2018-11-29
AU2018202197A1 (en) 2018-04-26
JP2019108389A (ja) 2019-07-04
AU2018202068A1 (en) 2018-04-19
EP2879688A1 (en) 2015-06-10
EP3485897A1 (en) 2019-05-22
JP2018012726A (ja) 2018-01-25
WO2014022551A1 (en) 2014-02-06
AU2013296493A1 (en) 2015-02-26
AU2013296493B2 (en) 2018-04-26
HK1210953A1 (en) 2016-05-13
CN104661670A (zh) 2015-05-27
EP3662921A1 (en) 2020-06-10
CN104768564A (zh) 2015-07-08
EP3300740A1 (en) 2018-04-04
JP2018016637A (ja) 2018-02-01
EP2879689A4 (en) 2015-12-16
CA2880648A1 (en) 2014-02-06
CA2880643A1 (en) 2014-02-06
EP3132800A1 (en) 2017-02-22
US20150283200A1 (en) 2015-10-08
CN110090304A (zh) 2019-08-06
US20150157685A1 (en) 2015-06-11
WO2014022552A1 (en) 2014-02-06
US20200000870A1 (en) 2020-01-02
US10201585B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
JP2018012726A (ja) アテローム性硬化症の処置方法
US12102659B2 (en) Methods for the prevention or treatment of heart failure
JP6641356B2 (ja) 疾患の予防及び治療のための方法及び組成物
JP2022116008A (ja) バース症候群の予防または治療のための方法及び組成物
CN103830719A (zh) 用于进行冠状动脉旁路移植手术的方法
CN103751763A (zh) 用于预防或治疗血管阻塞损伤的方法
JP2019052157A (ja) 左室リモデリングの予防または治療のための方法
JP2019052158A (ja) カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する
HK40007041A (en) D-arg-2&#39;6&#39;-dmt-lys-phe-nh2 for decreasing statin side effects
CA3122262A1 (en) Methods and compositions for the treatment of sengers syndrome
HK1178087A (en) Methods for performing a coronary artery bypass graft procedure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171129